BridgeBio Pharma (BBIO) Free Cash Flow: 2019-2025
Historic Free Cash Flow for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$110.0 million.
- BridgeBio Pharma's Free Cash Flow rose 39.10% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$585.9 million, marking a year-over-year decrease of 29.76%. This contributed to the annual value of -$521.7 million for FY2024, which is 1.39% up from last year.
- BridgeBio Pharma's Free Cash Flow amounted to -$110.0 million in Q3 2025, which was down 35.96% from -$80.9 million recorded in Q2 2025.
- BridgeBio Pharma's Free Cash Flow's 5-year high stood at $74.6 million during Q2 2024, with a 5-year trough of -$220.2 million in Q1 2024.
- In the last 3 years, BridgeBio Pharma's Free Cash Flow had a median value of -$144.4 million in 2023 and averaged -$131.0 million.
- Per our database at Business Quant, BridgeBio Pharma's Free Cash Flow tumbled by 246.06% in 2023 and then spiked by 165.66% in 2024.
- BridgeBio Pharma's Free Cash Flow (Quarterly) stood at -$136.4 million in 2021, then soared by 31.07% to -$94.0 million in 2022, then slumped by 33.19% to -$125.3 million in 2023, then slumped by 55.98% to -$195.4 million in 2024, then skyrocketed by 39.10% to -$110.0 million in 2025.
- Its Free Cash Flow stands at -$110.0 million for Q3 2025, versus -$80.9 million for Q2 2025 and -$199.6 million for Q1 2025.